论文部分内容阅读
目的探讨谷维素联合马来酸曲美布汀治疗肠易激综合征(IBS)的临床疗效。方法选取2012年5月—2014年8月株洲市三三一医院收治的IBS患者67例,按治疗方法不同将患者分为治疗组(35例)与对照组(32例)。对照组患者予以马来酸曲美布汀治疗,治疗组患者在对照组基础上加用谷维素治疗。观察两组患者临床疗效、治疗前后症状评分和症状频率评分、不良反应发生情况。结果治疗组患者总有效率高于对照组,差异有统计学意义(P<0.01);治疗前两组患者症状评分和症状频率评分比较,差异无统计学意义(P>0.05),治疗后治疗组患者症状评分和症状频率评分低于对照组,差异有统计学意义(P<0.05);两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。结论谷维素联合马来酸曲美布汀治疗IBS的临床疗效显著,可改善患者肠道功能,且不良反应小。
Objective To investigate the clinical efficacy of oryzanol and trimebutine maleate in the treatment of irritable bowel syndrome (IBS). Methods Sixty-seven patients with IBS admitted to Trinity Hospital of Zhuzhou City from May 2012 to August 2014 were divided into treatment group (35 cases) and control group (32 cases) according to different treatment methods. Patients in the control group were treated with trimebutine maleate. Patients in the treatment group were treated with oryzanol on the basis of the control group. The clinical efficacy, symptom scores and symptom frequency scores before and after treatment were observed in two groups of patients and the incidence of adverse reactions. Results The total effective rate in the treatment group was higher than that in the control group (P <0.01). There was no significant difference in symptom score and symptom frequency score between the two groups before treatment (P> 0.05) The score of symptom score and frequency of symptom were lower in the group than in the control group, the difference was statistically significant (P <0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P> 0.05). Conclusion The clinical efficacy of oryzanol and trimebutine maleate in the treatment of IBS is significant, which can improve the intestinal function and reduce the adverse reactions.